Menta Capital’s Akcea Therapeutics Inc AKCA Stock Holding History

Menta Capital’s Portfolio AKCA Stock Details AKCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,800	Closed	-$306K	–	637
2019 Q1	$306K	Buy	+10,800	New	+$315K	0.13%	276

Other funds holding AKCA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Menta Capital's AKCA Position: Q2 2019 in Review

Menta Capital sold out of Akcea Therapeutics Inc (AKCA) in Q2 2019, closing a stake of 10,800 shares — an estimated $306K sold.

Menta Capital first reported a position in AKCA in Q1 2019 and held it in 1 quarter. The position peaked at $306K in Q1 2019. 68 funds tracked by Wall St. Rank hold AKCA as of Q2 2019.

Menta Capital reported no remaining Akcea Therapeutics Inc position as of Q2 2019 after selling out during the quarter.
Menta Capital sold 10,800 Akcea Therapeutics Inc shares in Q2 2019, an estimated $306K.
Menta Capital first reported a position in Akcea Therapeutics Inc in Q1 2019 and held it in 1 quarter.
Menta Capital's Akcea Therapeutics Inc position peaked at $306K in Q1 2019.
68 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q2 2019.

Based on Menta Capital's 13F filing for Q2 2019, filed 7 Aug 2019.